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Edited by Varda RotterAbstract Senescence of mammalian cultured cells is essentially
organized by a machinery of cell division and cellular stresses
induced by various extracellular stimuli. Here, we show that in
mouse embryonic ﬁbroblasts (MEFs) culture in vitro, expression
of an inﬂammatory cytokine, interleukin-1b (IL-1b) and its
antagonist, IL-1 receptor antagonist (IL-1Ra) are induced by
senescence. The kinetics of IL-1b-expression was similar to that
of p38 activation during MEFs culture. We also found a
distinguishable accelerated senescence in cell growth in IL-1Ra
deﬁcient MEFs culture. Our results suggest that IL-1b signal-
ing pathway is involved in activation of p38 linked cellular
senescence.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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After serial cultivation, primary mammalian cells eventu-
ally reach a non-dividing state deﬁned as senescence [1]. Se-
nescence in human cells has been widely known as a result
driven by the shortening of telomeres (replicative senescence)
[2]. In contradistinction, it is also recognized that senescence
is induced by telomere-independent manners, as senescence is
known to be induced by inadequate culture conditions (cul-
ture shock) in mouse embryonic ﬁbroblasts (MEFs) [1]. Thus,
cellular senescence seems to be a mechanism for organism to
eliminate damaged cells and dodge the risk of developing
cancer in both murine and human systems [3]. However, the
molecular details of senescence remain mostly unknown.* Corresponding author. Fax: +81-562-46-3157.
E-mail address: michan@nils.go.jp (M. Maruyama).
Abbreviations: MEFs, mouse embryonic ﬁbroblasts; MAPKs, mito-
gen-activated kinases; IL-1, interleukin-1; IL-1Ra, IL-1 receptor
antagonist; IL-1Ra=, IL-1Ra deﬁcient; PD, population doublings;
SA-b-gal, senescence associated b-galactosidase; sIL-1Ra, secreted
type IL-1Ra; icIL-1Ra, intracellular IL-1Ra; IL-1RAcP, IL-1R
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doi:10.1016/j.febslet.2004.08.033Mitogen-activated kinases (MAPKs) are a widely conserved
family of serine/threonine protein kinases and regulate diverse
cellular responses. Activation of MAPKs occurs through
phosphorylation by MAPK kinases and this cascade is induced
by various extracellular stimuli such as growth factors, in-
ﬂammatory cytokines and oxdative stress [4]. Although it has
been reported that p38, one of the MAPKs family, plays an
important role in cellular senescence [5], the role of the p38
signaling cascade, especially which pathway is involved in the
activation of p38 during cellular senescence, is still contro-
versial.
In this study, we have attempted to identify the responsible
genes for regulating cellular senescence ofMEFs by suppression
subtractive hybridization [6,7]. We found here that pro-inﬂam-
matory cytokines, interleukin-1b (IL-1b) and IL-1 receptor an-
tagonist (IL-1Ra), were upregulated in senescent MEFs.
Especially, we provide an evidence that senescence associated
IL-1b expression culminates following IL-1Ra expression, but
in parallel with p38 activation. Furthermore, we demonstrate
thatMEFs prepared from IL-1Radeﬁcient (IL-1Ra=)mice [8]
show an accelerated cell growth decline in conjunction with p38
activation, suggesting that IL-1 signal is involved in p38 acti-
vation which plays a causative role of cellular senescence. Our
results are discussed in light of hitherto unknown function of
IL-1 signaling pathway in cellular senescence.2. Materials and methods
2.1. Preparation of MEFs and cell culture
C57BL/6 and IL-1Ra= (C57BL/6) mice [8] were used to prepare
MEFs as follows: E13.5 embryos were minced and trypsinized. The
resulting dispersed cells were cultured for 2 days, then cells were frozen
in aliquots and considered passage 0 (P0). Serial 3T3 cultivation was
done with slight modiﬁcation [9]. Brieﬂy, 1 · 106 cells were plated in 10
cm dish, 3 days later the cells were passaged in the same scale (1 106
cells). When the proliferation declined, cells were subcultured at a
splitting ratio of 1:3–1:1 every 3 days. Unless otherwise stated, MEFs
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Sigma, St. Louis, MO, USA) with 10% fetal bovine serum (FBS, In-
vitrogen, Carlsbad, CA, USA) and incubated at 37 C in 5% CO2. For
growth curves, population doublings (PD) were estimated at each
passage using the equation as described previously [10]. For synchro-
nization of the cell cycle at the G1/S boundary, MEFs were washed
three times with PBS and incubated in DMEM containing 0.1% FBS
for 72 h before preparation of total RNA.blished by Elsevier B.V. All rights reserved.
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For senescence associated b-galactosidase (SA-b-gal) activity, ap-
proximately 105 cells were placed in 3.5 cm dish and cultured for 3
days, then stained with SA-b-gal staining kit in accordance with the
manufacturer’s instructions (Cell Signaling Technology, Beverly, MA,
USA).
2.3. BrdU incorporation
Subconﬂuent MEFs were metabolically labeled with 10 lg/ml BrdU
for 4 h, trypsinized cells were ﬁxed and stained with FITC-conjugated
anti-BrdU antibody and 7-AAD in accordance with the manufac-
turer’s instructions (Becton Dickinson, Mountain View, CA, USA).
2.4. Subtractive suppression hybridization
Total RNA was prepared from young (day 4) and senescent (day 16)
MEFs using TRIZOL reagent (Invitrogen) and puriﬁed poly (A)þ
RNA using Nucleo TRAP mRNA kit (Macherey-Nagel, Duren,
Germany). 1 lg of total RNA was used for reverse transcription (RT)
experiment with SMART PCR cDNA Synthesis Kit (BD Clontech,
Palo Alto, CA, USA). PCR-Select cDNA subtraction kit was used for
subtractive hybridization in accordance with the manufacturer’s in-
structions (BD Clontech). Suppression PCR was performed to prepare
two cDNA pools, enriched for genes accumulated in senescent cells
(forward-subtracted) and in young cells (reverse-subtracted). Forward-
subtracted cDNA pool was screened by colony array using PCR-Select
Diﬀerential Screening Kit (BD Clonthech) and forward/reverse-
subtracted and non-subtracted young and senescent cDNA pools as
probes. The clones hybridized with only forward-subtracted probe or
both probes of forward-subtracted and non-subtracted senescent
cDNA pools were isolated and analyzed their sequences with GenBank
database.
2.5. Quantitative real-time RT-PCR analysis
RT experiments were done with SuperScript II (Invitrogen) and
quantitative real-time RT-PCR was performed with Smart Cycler
(Cepheid, Sunnyvale, CA, USA) and SYBR Green I system (Euro-
gentec, Seraing, Belgium). Relative mRNA expression levels of each
PD were obtained by the following formula: Relative mRNA
level¼ 2ðRt  EtÞ of various day in culture/2ðRt  EtÞ of reference. The threshold
cycle of b-actin and each experimental gene is represented as Rt and
Et, respectively. As the reference, the threshold cycle at day 4 was used
except IL-1b ampliﬁcation (day 7).
2.6. Western blot analysis
After treatment with 10 % trichloroacetic acid for 15 min, whole cell
lysates were prepared with the sample buﬀer described previously [11].
For the exogenous recombinant cytokine supplement experiments,
MEFs (day 2–5; 1 105 cells/3.5 cm dish) were treated with rIL-1b
(R&D Systems, Minneapolis, MN, USA) at concentrations as de-
scribed in the text. Lysates were prepared in the ice cold lysis buﬀer
described previously [12]. Primary antibodies were as follows: p38,
pp38 (Cell Signaling Technology); mouse IL-1Ra (M-20), mouse p16
(M-156) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); and
b-actin (Sigma). For secondary antibodies, we used Horseradish
peroxidase-conjugated donkey anti rabbit and sheep anti mouse
(Amersham, Little Chalfont, UK) and rabbit anti goat (Southern
Biotechnology, Birmingham, AL, USA) antibodies.
2.7. Primers
For real-time RT-PCR, the following primers were used: b-actin, 5-
AAG TGT GAC GTT GAC ATC CGT-3 (sense) and 5-GCA GCT
CAG TAA CAG TCC GC-3 (antisense); cytochrome b, 5-ATT ATC
GCG GCC CTA GCA AT-3 (sense) and 5-GGG CGG AAT ATT
AGG CTT CG-3 (antisense); amyloid-b precursor, 5-TGG CCC TCG
AGA ATT ACA TC-3 (sense) and 5-ACC GCA GGG ACA TTG
TAG AG-3 (antisense); ﬁbronectin 1, 5-TGG AGC CAT GTT CTC
AGC TT-3 (sense) and 5-AAG CAG AGG TGT CTG GGT GA-3
(antisense); intracellular IL-1Ra (icIL-1Ra), 5-CTG GGA AGG TCT
GTG CCA TA-3 (sense) and 5-CCA TGG GTG AGC TAA ACA
GG-3 (antisense); secreted type IL-1Ra (sIL-1Ra), 5-AGC ACA GGC
TGG TGA ATG AC-3 (sense) and 5-GTA GGG TCC CCA GCA
GAT TT-3 (antisense); IL-1a, 5-TTC TGC ATGGCA TTC TTAGG-
3 (sense) and 5-GGT GCA CAG TGA GAT TGG TC-3 (antisense);
IL-1b, 5-GCA GAG TTC CCC AAC TGG TA-3 (sense) and 5-GGT
TTC TTG TGA CCC TGA GC-3 (antisense); IL-1R type1, 5-CCACCA GAC AAG GAG-3 (sense) and 5-AGG CCT GGG TCC AGT
AGA AT-3 (antisense); IL-1R type2, 5-CTG GAA GGT GAA CCT
GTG GT-3 (sense) and 5-GGC GCC CTT ATA CCA CTG TA-3
(antisense).3. Results
3.1. Senescence-associated gene expression in MEFs
We have cultured MEFs derived from C57BL/6 mice as
described in materials and methods. As expected, the cells grew
vigorously for approximately the initial 10 days, then their
proliferation tended to decline (Fig. 1A). Around 2 weeks la-
ter, the cultures senesced and represented little change in cell
number for a few weeks. Eventually, proliferation resumed
because of appearance and outgrowth of immortal cell popu-
lation (over 45 days). To further characterize a reduction of
cell growth in MEFs culture by the capacity for DNA syn-
thesis, BrdU incorporation was measured at 2, 11–23 and 50
days in culture. After 4 h incubation with BrdU, the percent-
age of BrdU positive MEFs both in ‘young’ and ‘immortal’
cells represented around 45%, despite notable decrease below
15% incorporation shown in senescent MEFs (Fig. 1B). After
about 10–20 days in culture, the morphological change was
conﬁrmed by enlarged and ﬂattened shape and expression of
SA-b-gal, which is available biomarker for senescent cells
(Fig. 1C and data not shown). On the basis of the observation
above, we considered the MEFs between day 13 and 30 as
senescent. In order to identify the genes upregulated in se-
nescence, total RNA were prepared from young (day 4) and
senescent (day 16) MEFs and subjected to cDNA subtraction.
To eliminate a consideration of the genes involved in cell di-
vision, MEFs were synchronized with their cell cycle to G1
phase under serum starvation for 72 h before harvest. We
obtained 34 candidate clones involving the previously reported
senescence associated genes, such as ﬁbronectin [13], amyloid-
b precursor [14] and cytochrome b [15] (Fig. 1D) as well as
genes which were found in only expressed sequence-tagged
database, suggesting that our system did function well. Among
them, we noted IL-1Ra gene because its expression deter-
mined by quantitative real-time RT-PCR was dramatically
upregulated in senescent MEFs (about 14-fold. Fig. 1D.)3.2. Kinetics of IL-1 family gene expression and p38 activation
in MEFs senescence
Two forms of protein sIL-1Ra and icIL-1Ra type, has been
reported in mice [16]. Therefore, we next examined each
mRNA expression of sIL-1Ra or icIL-1Ra by quantitative
real-time RT-PCR using the unique primers for each IL-1Ra,
since the identiﬁed cDNA fragment was common to both
forms of IL-1Ra (Fig. 1D). As shown in Fig. 2A and B, we
found that sIL-1Ra and icIL-1Ra similarly increased more
than 20-fold by day 10, prior to senescent phase. Because IL-
1Ra is one of the IL-1 family member, we analyzed the gene
expression proﬁles of other IL-1 family agonists and their re-
ceptors in various culture days. About agonists, although IL-
1a mRNA showed only slight increase (less than 2-fold) in
senescent MEFs, IL-1b mRNA increased speciﬁcally through
the senescent phase (over 5-fold) and declined in immortal
MEFs (Fig. 2C and D). On the other hand, the expression of
functional receptor (IL-1R1) and ‘decoy receptor’ (IL-1R2)






























































































































































Fig. 2. mRNA expression of IL-1 family and its receptors. Each bar
represents the relative fold increase of mRNA level in various MEFs
indicated days in cultures compared with day 4 (day 7 for IL-1bÞ after
normalization to b-actin. Values represent means S.D. of four data
sets. (A) sIL-1Ra, (B) icIL-1Ra, (C) IL-1a, (D) IL-1b, (E) IL-1R1, (F)
IL-1RAcP, (G) IL-1R2. ND, not detected. Typical young and senes-
cent phases in culture days are described under panel (G).
Fig. 1. Characterization of cellular senescence in MEFs and senes-
cence-associated genes. (A) Growth curve of MEFs. Cells were culti-
vated as described in Section 2. The squares show the point at which
total RNA were prepared for suppression subtractive hybridization.
(B) Proliferation index in MEFs. Percentage of cells in S phase was
measured by BrdU incorporation. Young: day 2, senescent: day 11–23,
and immortal: day 50. (C) Comparison of SA-b-gal activity. Percent-
ages of SA-b-gal activity positive cells in young (day 1–4), senescent
(day 10–20) and immortal (day 30–40) MEFs are shown. Means values
and S.D. were derived from three experiments. (D) Expression of the
genes identiﬁed by cDNA subtraction screening. Each bar represents
the relative fold increase of mRNA level in G1-synchronized MEFs
at day 16 (black) compared with day 4 (white) after normalization to
b-actin.
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once and only both IL-1Ra levels were upregulated again
through senescence phase (day 13–34). Concerning another
essential component for IL-1 signaling, IL-1R accessory pro-
tein (IL-1RAcP), an ubiquitous expression was detected in
early phase of senescence and precise increase was observed
following IL-1b expression (Fig. 2F).Because it has been reported that IL-1 can activate p38
MAPK [17], which plays a causative role in senescence [5], we
next examined the kinetics of p38 activation in MEFs (Fig. 3).
The accumulation of phosphorylated p38 (pp38) protein was
increased drastically until day 21 and this level was continued
during senescence paralleled with that of p16 cell cycle inhib-
itor. Combining the kinetics of IL-1b mRNA expression with
this result, it is strongly suggested that IL-1b functions actively
in concert with pp38 in MEFs senescence. On the other hand,
pp38 level was low at early days in culture when IL-1Ra was
increasing in mRNA and the following protein expression (day
9–15; Figs. 2A, B and 3). This suggests that IL-1Ra negatively
regulates p38 activation and senescence until IL-1b surpass
IL-1Ra in expression level.
Fig. 3. IL-1 related proteins increased with cellular senescence in
C57BL/6 MEFs. Immunoblot analysis of pp38, p38, p16 and icIL-1Ra
expression was carried out with cell extracts from various MEFs in-
dicated days in cultures. The protein levels normalized to those of b-
actin (p16) or p38 (pp38) are shown as folded values relative to that of
MEFs at day 9. Day 9 and day 15–33 correspond to young and
senescent phase, respectively.
Fig. 5. IL-1b induced activation of p38 in MEFs. Immunoblot analysis
of pp38 in C57BL/6 (wt) and IL-1Ra= MEFs (day 5) after incu-
bation with increasing amounts of rIL-1b described for 5 min. Protein
level of pp38 is normalized to p38 and shown as relative value.
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culture
In view of the physiological eﬀect by IL-1 family in cellular
senescence, we next cultured MEFs prepared from IL-1Ra=
mice. All in all, IL-1Ra= MEFs displayed similar morpho-
logical changes to wild-type (data not shown), however, we
noticed that the primary proliferation in IL-1Ra= MEFs
declined slightly earlier than wild-type control (Fig. 4A). This
diﬀerence was manifested and statistically signiﬁcantFig. 4. Cellular senescence is hastened in IL-1Ra= MEFs. (A)
Growth curves of MEFs from C57BL/6 (wt) (open circle) or IL-
1Ra= (black square) mice. The data represent meansS.D. of three
independent experiments. Statistical signiﬁcance for means of PD per 3
days was determined by ANOVA. P < 0:01. (B) The proliferation
index in early senescent MEFs from wt (open bar) or IL-1Ra=
(dotted bar) mice was determined by BrdU incorporation. The data
shown are two sets of results representing meansS.D. of three in-
dependent experiments. (C) Immunoblot analyses of p38, pp38 and
p16 expression were carried out in various IL-1Ra= MEFs indicated
days in cultures. Each protein level is normalized to p38 (for pp38) or
b-actin (for p16) and described as relative value to IL-1Ra= MEFs at
day 9.(P < 0:01) in day 9–12. To conﬁrm this reproducible reduction
in cell proliferation, BrdU incorporation was measured in
IL-1Ra= MEFs culture. As shown in Fig. 4B, BrdU incor-
poration of IL-1Ra= MEFs was obviously lower than wild-
type in the early phase of senescence, day 10, although the
diﬀerence was not so distinguishable in the following senescent
phase. The young (day 5) wild-type and IL-1Ra= MEFs
showed comparable population of spontaneously dead cells in
annexin-V assay (data not shown), therefore we concluded that
this reduced proliferation of IL-1Ra= MEFs was not the
result of increased cell death.
To gain more insights into the molecular pathway with the
MEFs senescence, we next examined the kinetics of p38 acti-
vation in IL-1Ra= MEFs. As contrasted with wild-type
MEFs in Fig. 3, both a striking p38 activation and p16 accu-
mulation were observed at earlier days in IL-1Ra= MEFs
culture (Fig. 4C). These results suggest that under the absence
of IL-1Ra, IL-1b can smoothly activate the downstream p38
and subsequently promote a relative swift cellular senescence
in MEFs. To conﬁrm this, we investigated whether p38 is ac-
tivated more easily without IL-1Ra in MEFs. As shown in
Fig. 5, signiﬁcant phosphorylation of p38 was conﬁrmed in
dose dependent manner only 5 min after supplement of rIL-1b.
It is worth to note that IL-1Ra= MEFs represent about 2-
fold sensitivity to rIL-1b at the 0.5–50 ng/ml of dose. Thus, we
concluded that IL-1 signaling was involved in p38 activation
during senescence and IL-1Ra have somehow negative func-
tion against senescence through inhibition of IL-1 signaling in
MEFs.4. Discussion
Recently, it has been reported that p38 MAPK plays an
important role in cellular senescence, but which pathway is
involved in p38 activation in senescent cells is still unknown. In
this study, we focused on inﬂammatory cytokine IL-1b and IL-
1Ra, because mRNA expression level of these genes increased
during senescence of MEFs (Fig. 2A, B and D). To date, al-
though it has been reported that IL-1a or even both IL-1a=b
expression elevated in senescence of human endothelial cells
[18] or ﬁbroblast cells [19], they simply discussed about IL-
1-induced gene expression during senescence. Thus, we exam-
ined the function of IL-1b signaling including IL-1Ra for
cellular senescence mediated by activation of p38 MAP kinase.
In the present study, we showed that the kinetics of IL-1b
expression was correlated with the kinetics of p38 activation in
MEFs senescence (Figs. 2 and 3) and in IL-1Ra= MEFs, p38
activation and growth reduction were likely to be induced
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IL-1 signal is involved in activation of p38 during senescence.
The coupled age-related increase in IL-1b concentration and
p38 activation has been recently reported in neuronal tissue
from rat brain [20,21]. This information surely lends further
support to notion that IL-1b signaling with p38 activation is
involved in MEFs senescence in vitro as well as in the aged rat
brain.
IL-1Ra expression was increasing during early days in cul-
ture and at that phase p38 activation was suppressed. But at
day 21, p38 was activated intensively though IL-1Ra expres-
sion level was high (Figs. 2 and 3). It is reported that 100-fold
or greater levels of IL-1Ra over IL-1 are necessary to func-
tionally inhibit the biologic eﬀects of IL-1 on target cells [22].
So we concluded that IL-1Ra was overcome by IL-1b on day
21 (Fig. 2D).
In this paper, our results indicate that IL-1Ra function as a
negative regulator to senescence through inhibition of IL-1
signaling. Alternatively, it has been recently reported that IL-
1Ra allelic polymorphisms aﬀect replicative lifespan of human
endothelial cells [23] and icIL-1Ra expression preserved young
phenotype in endometrial stromal ﬁbroblasts [24]. And there is
another report that IL-1Ra= mice represented early mor-
tality compared to wild-type mice [25]. Thus, we strongly
suggest here that preventive function of IL-1Ra in IL-1 sig-
naling involved senescence must be considered indistinguish-
able in terms of both in vitro and in vivo.
It is also showed that imbalance between IL-1b and IL-1Ra
is a trigger in many diseases, especially those suﬀered by elderly
people such as cancer and rheumatoid arthritis [26]. Hence, the
physiological role of IL-1 family is seemed to be critical for the
health in aged people. In addition, there is another report that
pp38 was increased in the Alzheimer’s disease brain relative to
age matched normal human brain [27], and we observed that
mRNA expression of both types of IL-1Ra was upregulated in
senescent human ﬁbroblasts cells, MRC-5 (N.U. and M.M.,
unpublished data). Therefore, in view of clinical point, to re-
veal the physiological role of IL-1b and IL-1Ra in senescent
MEFs will be an inevitable issue for providing useful thera-
peutic information of these diseases.
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